Article
Oncology
Jia-Yi Huang, Xiao-Feng Xie, Xue-Lian Chen, Qiu-Yi Zhang, Li-Ping Chen, Xue Bai, Xiao-Feng Lan, Lin Song, Jin-Feng Guo, Cai-Wen Du
Summary: This study aimed to evaluate the efficacy and safety of anlotinib combined with chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). The results showed that anlotinib combined with chemotherapy improved progression-free survival and overall survival, indicating certain efficacy, and the toxicity was acceptable.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Miao Xiang, Xiyue Yang, Surong Ren, Huan Du, Lidan Geng, Li Yuan, Yixue Wen, Binwei Lin, Jie Li, Yu Zhang, Gang Feng, Xiaobo Du
Summary: The combination of anlotinib and S-1 showed good antitumor activity and manageable toxicity in patients with stage IV NSCLC in third- or later-line treatment, achieving a 30% objective response rate.
Article
Oncology
Qingli Cui, Yuefeng Mao, Yanhui Hu, Dongyang Ma, Huaimin Liu
Summary: This study explored the efficacy and safety of anlotinib in patients with recurrent or metastatic endometrial cancer. The results showed that anlotinib is effective and well tolerated in this patient population. Age and prior lines of treatment were identified as important factors in predicting progression-free survival and overall survival.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Qin Xu, Junjie Wang, Yang Sun, Yibin Lin, Jing Liu, Yanhong Zhuo, Zhangzhou Huang, Songhua Huang, Ying Chen, Li Chen, Meifang Ke, Li Li, Zirong Li, Junping Pan, Yanwen Song, Rongqiang Liu, Chuanben Chen
Summary: This study investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1-positive advanced cervical cancer patients. The results showed a high objective response rate and disease control rate of sintilimab plus anlotinib in these patients, along with a certain proportion of treatment-related adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan
Summary: This study evaluated the efficacy and safety of anlotinib in patients with metastatic HER2-negative breast cancer, showing objective efficacy with tolerable toxicity. Additionally, dynamic changes in circulating tumor DNA may be predictive of tumor response.
CANCER BIOLOGY & MEDICINE
(2021)
Article
Oncology
Yihebali Chi, Yongqian Shu, Yi Ba, Yuxian Bai, Baoli Qin, Xiuwen Wang, Jianping Xiong, Nong Xu, Helong Zhang, Jianfeng Zhou, Jianming Xu, Ying Cheng, Jifeng Feng, Chunhong Hu, Yigui Chen, Zhendong Chen, Jufeng Wang, Chengxue Dang, Jianhong Wang, Yiye Wan, Yong Tang, Donglin Wang, Jiang Liu, Minhui Wu, Yanhong Deng, Xingwen Li, Yongqiang Li, Jian Dong, Da Jiang, Guisheng Li, Qiong Wu, Jin Li, Yujuan Qi, Yongkun Sun, Jianqiang Cai
Summary: In summary, the study showed that treatment with Anlotinib significantly prolonged progression-free survival in patients with refractory metastatic colorectal cancer, with improvements in objective response rate and disease control rate. However, overall survival was similar between the two groups.
Article
Oncology
Pengbo Deng, Chengping Hu, Cen Chen, Liming Cao, Qihua Gu, Jian An, Ling Qin, Min Li, Baimei He, Juan Jiang, Huaping Yang
Summary: Anlotinib combined with platinum-etoposide is an effective and safe therapy for first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC).
Article
Multidisciplinary Sciences
Jingyang Lin, Qingxia Fang, Xiaochun Zheng
Summary: This study evaluated the cost-effectiveness of anlotinib as a first-line treatment for metastatic renal cell carcinoma (mRCC) compared to sunitinib in China. The results showed that anlotinib is a more effective and less costly treatment strategy.
Article
Oncology
Mehmet Akce, Batoul Farran, Jeffrey M. Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L. Shaib, Christina Wu, Olatunji B. Alese, Maria Diab, Gregory B. Lesinski, Bassel F. El-Rayes
Summary: The combination of nivolumab and metformin did not demonstrate efficacy in patients with MSS CRC. While metformin alone did not show significant immune modulation effects, the dual treatment showed trends in increasing tumor-infiltrating leukocytes and decreasing naive CD8+T cells in patient tissues.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Endocrinology & Metabolism
Nai-si Huang, Wen-jun Wei, Jun Xiang, Jia-ying Chen, Qing Guan, Zhong-wu Lu, Ben Ma, Guo-hua Sun, Yu-long Wang, Qing-hai Ji, Yu Wang
Summary: The study showed that anlotinib exhibited good antitumor activity in neoadjuvant treatment of locally advanced thyroid cancer, with the majority of patients achieving surgical resection. Adverse events were mostly mild and manageable. This suggests that anlotinib neoadjuvant treatment represents a new therapeutic option for locally advanced thyroid cancer.
Article
Medicine, General & Internal
Yu Fang, Ning Su, Qihua Zou, Yi Cao, Yi Xia, Linquan Tang, Xiaopeng Tian, Panpan Liu, Qingqing Cai
Summary: The study found that anlotinib monotherapy showed promising anti-tumor activities and disease control for RM-NPC patients, with a tolerable toxicity profile.
Article
Oncology
W. Kimryn Rathmell, R. Bryan Rumble, Peter J. Van Veldhuizen, Hikmat Al-Ahmadie, Hamid Emamekhoo, Ralph J. Hauke, Alexander Louie, Matthew Milowsky, Ana M. Molina, Tracy L. Rose, Shankar Siva, Nicholas G. Zaorsky, Tian Zhang, Rubina Qamar, Terry M. Kungel, Bryan Lewis, Eric A. Singer
Summary: The article provides recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC), including diagnosis, treatment, and participation in clinical trials.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Shuiling Jin, Ruihua Zhao, Chuang Zhou, Qian Zhong, Jianxiang Shi, Chang Su, Qinglong Li, Xiaoxing Su, Huabin Chi, Xu Lu, Guozhong Jiang, Renyin Chen, Jinming Han, Miao Jiang, Shishi Qiao, Jingjing Liu, Min Song, Lijie Song, Yabing Du, Zhiwei Chang, Meng Wang, Meilian Dong, Yali Zhong, Pu Yu, Xiaojian Zhang, Hong Zong
Summary: This study evaluated the feasibility and tolerability of sintilimab plus anlotinib as second-line treatment for advanced BTC patients and found that this regimen showed encouraging anti-tumor activity. Genomic profiling and gut microbiome were explored as potential biomarkers for this regimen.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan
Summary: This study investigated the efficacy and safety of PD-1 blockade with sintilimab plus anti-angiogenic treatment with anlotinib in patients with non-small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations. The results showed that this combination therapy demonstrated durable efficacy and was generally well tolerated in these patients.
Article
Oncology
Jing Huang, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Yan Song, Jie He
Summary: A randomized trial in Chinese hospitals showed that anlotinib significantly improved progression-free survival in patients with advanced ESCC who had previously undergone chemotherapy, with common adverse events including hypertension, decreased appetite, and hyponatremia. This study suggests that antiangiogenic therapy could be an important therapeutic target for advanced ESCC.